ChiCTR2100051569
结束
/
/
/
2021-09-27
/
/
新型冠状病毒肺炎(COVID-19)
Post COVID-19 pulmonary complications: a single center experience
Post COVID-19 pulmonary complications: a single center experience
46000
The current study aims to present a series of cases whom have developed short-term pulmonary complications after recovering from COVID-19.
连续入组
回顾性研究
No
N/A
Smart health tower
/
19
/
2021-01-05
2021-07-29
/
Those patients were included who were infected with SARS-CoV-2 and developed pulmonary symptoms in less than 6 months of recovery, or already had the symptoms during active infection but persisted even after recovery. These symptoms should be clearly related to COVID-19 infection.；
登录查看Known cases of lung cancer, tuberculosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and other chronic lung diseases were excluded from the study.；
登录查看Al-Jamhori teaching hospital
46000
药明康德2024-10-25
药渡2024-10-25
医麦客2024-10-25
小药说药2024-10-25
触界生物2024-10-24
磐霖资本2024-10-24
Pharma CMC2024-10-24
Pharma CMC2024-10-24
瑞博小核酸2024-10-24
君实医学2024-10-24
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
